Global Healthcare Policy Analysis 2012 ' Regulatory, Pricing, and Reimbursement Assessment

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Global Healthcare Policy Analysis 2012 ' Regulatory, Pricing, and
Reimbursement Assessment
Published on August 2012

Report Summary

Global Healthcare Policy Analysis 2012 ' Regulatory, Pricing, and Reimbursement Assessment

Summary

GlobalData's "Global Healthcare Policy Analysis 2012 ' Regulatory, Pricing, and Reimbursement Assessment" provides an in-depth
look at the policy initiatives and regulations shaping pharmaceutical markets around the world. Focusing on the global regulatory
landscape in 2012, the report integrates in-depth research into the policies of major international markets with expert insight to reveal
the opportunities and threats that the pharmaceutical industry is facing. Clients can use this report for strategic planning to tackle the
challenges of developed markets and discover prospects in emerging markets. The report covers major healthcare policy initiatives,
regulatory changes and key drug approvals, and examines the myriad of regulatory issues that are constantly affecting
pharmaceutical and biotechnology players.

Scope

- The report provides an in-depth look at changes in healthcare policy and regulations in key countries, including background
information and a detailed look at the first half of 2012.
- The report provides analysis of the key policy and regulatory changes employed by governments in different pharmaceutical markets
and how they are affecting pharmaceutical companies.
- The report contains case studies of regulatory issues that have cropped up in various countries and what these events mean for the
industry at large.
- The report includes analysis of important events in 2012 that will shape the global healthcare market into the future.

Reasons to buy

- Be prepared for the challenges in the biopharmaceutical industry that are being created by changes in different countries' healthcare
policy.
- Understand current regulatory decisions or actions and upcoming regulatory changes to avoid unnecessary setbacks in the
development, approval, and commercial launch of pharmaceutical products.
- Identify the significant changes that are taking place in important pharmaceutical markets such as the United States, Japan, China,
and India.
- Organize your sales and marketing efforts by identifying the international markets that are poised for strong growth as well as the
countries where market access will be more challenging.

Table of Content

1 Table of Contents
1 Table of Contents 3

Global Healthcare Policy Analysis 2012 ' Regulatory, Pricing, and Reimbursement Assessment (From Slideshare) Page 1/6


1.1 List of Tables 4
2 Introduction 5
2.1 Recent Related Reports 6
2.2 Upcoming Related Reports 6
3 United States 7
3.1 Overview 7
3.2 Regulatory Update 7
3.2.1 Evolving Guidelines for Biosimilars 7
3.2.2 Merck & Co. Post-Marketing Study Warning 10
3.2.3 FDA Guidance on Cargo Theft 11
3.2.4 Moving Drugs from Prescription-Only to Over-the-Counter 12
3.2.5 Notable US Drug Approvals 13
3.3 Policy Update; Healthcare Reform 14
3.3.1 Supreme Court Backs the Affordable Care Act 15
3.3.2 Background on the Healthcare Supreme Court Case 15
3.3.3 Affordable Care Act Provisions Already Implemented 16
3.3.4 New in 2012: ACOs, W-2 Tax Reporting, and Addressing Disparities 17
3.3.5 The Future of the Affordable Care Act: Taxes 18
3.3.6 Update of the Prescription Drug User Fee Act 19
3.4 Pricing and Reimbursement 23
3.5 Intellectual Property 25
3.6 Case Study ' KV Pharmaceuticals 26
4 European Union 28
4.1 Overview 28
4.2.1 UK NICE Updates 28
4.3 Policy Update - Healthcare Reform 32
4.3.1 Healthcare Reform in the United Kingdom 32
4.3.2 'Patent Box' to Encourage Pharmaceutical Investment in the UK 34
4.3.3 German Healthcare Reform Challenges Drug Pricing 34
4.4.1 German Drug Pricing Determinations to Date 36
4.4.2 Unintended Consequences of Strict Pricing Policies 37
5 Japan 39
5.1 Overview 39
5.2.1 Notable Drug Approvals 39
5.4.1 Pricing for Newly Approved Drugs 43
5.4.2 Pricing Policy for Generic Drugs 44
5.4.3 Results of 2012 Price Revisions 44
6 China 46
6.1 Overview 46
6.2.1 Efforts against Counterfeit Drugs 46
6.2.2 Crackdown on Ephedrine 46



6.3.1 Introduction to the 12th Five-Year Plan 46
6.3.2 Healthcare Reform 47
6.3.3 Healthcare Reform Progress in 2012 48
7 India 51
7.1 Overview 51
7.2.1 Drug Approvals Controversy 51
7.2.2 Guidelines for Biosimilars 52
7.4.1 Pricing 52
7.4.2 Intellectual Property Scuffle Prompts Pricing Changes 53
8 Brazil 54
8.1 Overview 54
8.4.1 Background 55
8.4.2 Update on Drug Prices in 2012 56
8.6 Mergers and Acquisitions Activity 57
8.6.1 Valeant's Brazilian Spending Spree 57
8.6.2 Merck & Co. Announces Brazilian Joint Venture 57
8.6.3 Takeda Purchases Multilab 57
8.6.4 UCB Acquires Controlling Interest in Meizler 57
8.6.5 GE Healthcare Acquires Xpro 58
9 Appendix 59
9.1 Bibliography 59
9.2 Abbreviations 61
9.3 Methodology 62
9.3.1 Coverage 62
9.3.2 Secondary Research 63
9.3.3 Expert Panel Validation 63
9.4 About the Authors 63
9.5 About GlobalData 64
9.6 Contact Us 64
9.7 Disclaimer 64

List of Tables

Table 1: Provisions of the Affordable Care Act and Effective Dates 16
Table 2: Timeline of Seroquel Intellectual Property Case 25
Table 3: German Drug Reimbursement Decisions 36
Table 4: Flowchart for Determining New Drug Reimbursement 43


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Global Healthcare Policy Analysis 2012 ' Regulatory, Pricing, and Reimbursement Assessment

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Global Healthcare Policy Analysis 2012 ' Regulatory, Pricing, and Reimbursement Assessment

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Mehr von ReportLinker.com

Mehr von ReportLinker.com (20)

Global Healthcare Policy Analysis 2012 ' Regulatory, Pricing, and Reimbursement Assessment